Please assess the completion status of the following clinical trial:

Trial Title: SC12267 (4SC-101) for Treatment of Patients With Inflammatory Bowel Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Criteria regarding Crohn´s Disease:~* Established diagnosis of CD, confirmed by standard criteria (e.g. endoscopy, ultrasound, X-ray)~* Patients must be in clinical remission (Crohn's Disease Activity Index \[CDAI\] \<150 points) on steroid therapy for at least 2 weeks~* Confirmed steroid-dependency of CD: patients who are either~  1. unable to taper steroids completely within 3 months of starting steroids, without recurrent active disease, or~ 2. who have a relapse within 2 months of stopping steroids~* Individual threshold\* dose of previous relapses should be equal or less than 20 mg/day Prednisolone or equivalent steroid dose~* Patients with stable glucocorticosteroid therapy between 20 and 40 mg/day Prednisolone or equivalent steroid dose for the previous week~Criteria regarding Ulcerative Colitis:~* Established diagnosis of UC, confirmed by standard criteria (e.g. endoscopy, ultrasound, X-ray)~* Patients must be in clinical remission (Clinical Activity Index \[CAI\] \<4 points) on steroid therapy for at least 2 weeks~* Confirmed steroid-dependency of UC: patients who are either~  1. unable to taper steroids completely within 3 months of starting steroids, without recurrent active disease, or~ 2. who have a relapse within 2 months of stopping steroids~* Individual threshold\* dose of previous relapses should be equal or less than 20 mg/day Prednisolone or equivalent steroid dose~* Patients with stable glucocorticosteroid therapy between 20 and 40 mg/day Prednisolone or equivalent steroid dose for the previous week~(\* The threshold dose is that dose at which the patient experienced the relapses)~Criteria regarding general requirements:~* Men and women, 18 to 70 years of age~* Written informed consent~* Negative pregnancy test at screening in females of child-bearing potential~* Males willing to use condoms or to be sexually abstinent~* Use of appropriate contraceptive methods for females of childbearing potential one month before, throughout the course of the study and one month after study termination. This must be a combination of the following:~  1. a highly effective method of first choice = a method with a low failure rate (i.e. less than 1% per year) like sexual abstinence, combined oral contraceptives, implants, injectables, some Intra Uterine Devices (IUDs), vasectomized partner~     together with~ 2. a method of second choice like condom, diaphragm, or cup pessary~Exclusion Criteria:~Criteria regarding gastrointestinal conditions:~* Short bowel syndrome~* Ileostomy, colostomy or rectal pouch~* Relapse during screening~Criteria regarding medical history:~* History of or existence of active tuberculosis~* History of or existence of urolithiasis~* History of or existence of human immune deficiency virus (HIV), Hepatitis B or C~* History of malignancy within the past five years (excluding basal cell carcinoma of the skin)~* Previous opportunistic infection~* History of serious drug sensitivity~Criteria regarding concomitant diseases:~* Significant cardiac arrhythmia, bradycardia or tachycardia or any other significant finding in the electrocardiogram (ECG)~* Congestive heart failure~* Uncontrolled arterial hypertension~* Uncontrolled asthma~* Renal disease~* Renal insufficiency defined as glomerular filtration rate (GRF) \<50 ml/min/1.73 m² (estimated GRF according to Cockcroft-Gault)~* Psychiatric illness~* Known or suspected immunodeficiency~* Laboratory abnormalities: hemoglobin \<8.5 g/dl, white blood cell count \<3500/mm³, platelet count \<125 000/mm³, clinically relevant elevation of liver enzymes, serum creatinine level \>=1.4 mg/dl, hematuria (\>=10 erythrocytes/field on dipsticks)~Criteria regarding concomitant circumstances:~* Pregnancy, lactation~* History of alcohol and/or drug dependence~* Heavy smoking (more than 20 cigarettes per day)~* Use of prohibited drugs or treatments~* Patient not able or not willing to follow study procedures due to physical or psychological limitations or language problems~* Participation in another investigational drug or vaccine trial within the last three months or concurrently with this study~* Vaccination with life attenuated viruses within 4 weeks prior to study start~* Patient with any medical condition which, in the opinion of the investigator or his designee, could jeopardize or compromise the ability of the patient to participate in the trial~* Patients possibly dependent on the investigator or the sponsor

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).